Embio Limited has successfully secured a significant investment from True North, resulting in the investor acquiring a minority stake in the company. This strategic transaction was navigated with the expert legal guidance of Khaitan & Co.
The legal team from Khaitan & Co was spearheaded by Partner Bhavik Narsana, who received robust support from Senior Associate Ipshita Dey, as well as Associates Kamayani Mittal, Pragya Mishra, and Sakshi Mehta.
Comprehensive Legal Due Diligence
The legal due diligence was meticulously conducted under the leadership of Bhavik Narsana, with Consultant Shweta Dwivedi and Associates Kamayani Mittal and Pragya Mishra playing key roles.
Employment Legal Due Diligence
Partner Deepak Kumar and Associate Ananya Gandhi handled the employment aspects of the legal due diligence.
Intellectual Property Legal Due Diligence
On the intellectual property front, the team was led by Partner Shailendra Bhandare, with significant contributions from Counsel Janaksinh Jhala, Principal Associate Abhishek Kumar, Senior Associate Vaishali Adhikari, and Associate Shouraseni Chakraborty.
More Read
Real Estate Legal Due Diligence
Real estate due diligence was overseen by Partners Amit Wadhwani, Mudit Shah, and Pavithra Thammaiah, along with Principal Associate Shrey Bheda, and Associates Hanumant Chauhan, Nidhi Marakana, and Esha Sanjyot Shah.
Litigation Legal Due Diligence
The litigation aspect was managed by Partners Raj R. Panchmatia, Peshwan Jehangir, and Divya Chaturvedi, supported by Counsel Srishti Rai, Senior Associates Ayush Jain and Niyathi Kalra, and Associate Chandan Kumar.
Embio Limited is recognized for its expertise in manufacturing complex, high-value active pharmaceutical ingredients (APIs) and advanced intermediates. The company has carved out a market leadership position in controlled substances across multiple therapeutic areas, including nasal decongestants, ADHD medications, treatments for Parkinson’s disease, and anti-epileptics.
This investment by True North is expected to catalyze Embio’s next growth phase, enabling further investments in research and development, talent acquisition, expansion of its Dahej facility, and scaling of its Contract Development and Manufacturing Organization (CDMO) services.
